Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Tax Provisions (2019 - 2025)

Historic Tax Provisions for Neurocrine Biosciences (NBIX) over the last 6 years, with Q4 2025 value amounting to $85.7 million.

  • Neurocrine Biosciences' Tax Provisions rose 4403.36% to $85.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $226.8 million, marking a year-over-year increase of 5673.81%. This contributed to the annual value of $226.8 million for FY2025, which is 5673.81% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Tax Provisions of $85.7 million as of Q4 2025, which was up 4403.36% from $82.3 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Tax Provisions peaked at $85.7 million during Q4 2025, and registered a low of -$26.7 million during Q1 2023.
  • For the 4-year period, Neurocrine Biosciences' Tax Provisions averaged around $31.5 million, with its median value being $32.5 million (2023).
  • Examining YoY changes over the last 5 years, Neurocrine Biosciences' Tax Provisions showed a top increase of 150000.0% in 2021 and a maximum decrease of 42666.67% in 2021.
  • Neurocrine Biosciences' Tax Provisions (Quarter) stood at $8.0 million in 2021, then soared by 531.25% to $50.5 million in 2023, then grew by 17.82% to $59.5 million in 2024, then soared by 44.03% to $85.7 million in 2025.
  • Its Tax Provisions was $85.7 million in Q4 2025, compared to $82.3 million in Q3 2025 and $52.0 million in Q2 2025.